Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis
David G. Kirsch,1,2,3,*
Philip M. Santiago,1
Emmanuelle di Tomaso,2
Julie M. Sullivan,3
Wu-Shiun Hou,1,
Talya Dayton,1
Laura B. Jeffords,3
Pooja Sodha,1
Kim L. Mercer,1
Rhianna Cohen,1
Osamu Takeuchi,4
Stanley J. Korsmeyer,4,
Roderick T. Bronson,5
Carla F. Kim,1,
Kevin M. Haigis,1,||
Rakesh K. Jain,2
Tyler Jacks1,6,¶
Abstract:
Acute exposure to ionizing radiation can cause lethal damageto the gastrointestinal (GI) tract, a condition called the GIsyndrome. Whether the target cells affected by radiation tocause the GI syndrome are derived from the epithelium or endotheliumand whether the target cells die by apoptosis or other mechanismsare controversial issues. Studying mouse models, we found thatselective deletion of the proapoptotic genes Bak1 and Bax fromthe GI epithelium or from endothelial cells did not protectmice from developing the GI syndrome after sub–total-bodygamma irradiation. In contrast, selective deletion of p53 fromthe GI epithelium, but not from endothelial cells, sensitizedirradiated mice to the GI syndrome. Transgenic mice overexpressingp53 in all tissues were protected from the GI syndrome afterirradiation. These results suggest that the GI syndrome is causedby the death of GI epithelial cells and that these epithelialcells die by a mechanism that is regulated by p53 but independentof apoptosis.
1 David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. 2 Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. 3 Departments of Radiation Oncology and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27708, USA. 4 Dana Farber Cancer Institute, Boston, MA 02115, USA. 5 Tufts University School of Medicine and Veterinary Medicine, North Grafton, MA 05136, USA. 6 Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
* Present address: Departments of Radiation Oncology and Pharmacologyand Cancer Biology, Duke University Medical Center, Durham,NC 27708, USA.
Present address: Genomics Research Center, Academia Sinica,Taipei 11529, Taiwan.
Deceased.
Present address: Department of Genetics, Harvard Medical Schooland Stem Cell Program, Childrens Hospital, Boston, MA02118, USA.
||Present address: Massachusetts General Hospital Cancer Centerand Harvard Medical School, Charlestown, MA 02129, USA.
¶ To whom correspondence should be addressed. E-mail: tjacks{at}mit.edu
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORS' CHOICE
Paula A. Kiberstis (2 February 2010) Sci. Signal.3 (107), ec42.
[DOI: 10.1126/scisignal.3107ec42] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.
Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage.
J. J. Gierut, P. S. Mathur, W. Bie, J. Han, and A. L. Tyner (2012)
Mol. Cancer Ther.
11, 2311-2320
|Abstract »|Full Text »|PDF »
p53 Functions in Endothelial Cells to Prevent Radiation-Induced Myocardial Injury in Mice.
C.-L. Lee, E. J. Moding, K. C. Cuneo, Y. Li, J. M. Sullivan, L. Mao, I. Washington, L. B. Jeffords, R. C. Rodrigues, Y. Ma, et al. (2012)
Science Signaling
5, ra52
|Abstract »|Full Text »|PDF »
Omcg1 is critically required for mitosis in rapidly dividing mouse intestinal progenitors and embryonic stem cells.
T. Leguillier, S. Vandormael-Pournin, J. Artus, M. Houlard, C. Picard, F. Bernex, S. Robine, and M. Cohen-Tannoudji (2012)
Biology Open
1, 648-657
|Abstract »|Full Text »|PDF »
The diagnostic value of [18F]-FDG-PET/CT in hematopoietic radiation toxicity: a Tibet minipig model.
C. Chen, L.-M. Yan, K.-Y. Guo, Y.-J. Wang, F. Zou, W.-W. Gu, H. Tang, Y.-L. Li, and S.-J. Wu (2012)
J Radiat Res
53, 537-544
|Abstract »|Full Text »|PDF »
Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer.
J. Tian, H. Zhao, R. Nolley, S. W. Reese, S. R. Young, X. Li, D. M. Peehl, and S. J. Knox (2012)
Clin. Cancer Res.
18, 3366-3376
|Abstract »|Full Text »|PDF »
Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response.
S. K. Liu, S. A. S. Bham, E. Fokas, J. Beech, J. Im, S. Cho, A. L. Harris, and R. J. Muschel (2011)
J Natl Cancer Inst
103, 1778-1798
|Abstract »|Full Text »|PDF »
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.
E. C. Josefsson, C. James, K. J. Henley, M. A. Debrincat, K. L. Rogers, M. R. Dowling, M. J. White, E. A. Kruse, R. M. Lane, S. Ellis, et al. (2011)
J. Exp. Med.
208, 2017-2031
|Abstract »|Full Text »|PDF »
Uncoupling p53 Functions in Radiation-Induced Intestinal Damage via PUMA and p21.
B. J. Leibowitz, W. Qiu, H. Liu, T. Cheng, L. Zhang, and J. Yu (2011)
Mol. Cancer Res.
9, 616-625
|Abstract »|Full Text »|PDF »
Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators.
B. Movsas, B. Vikram, M. Hauer-Jensen, J. E. Moulder, E. Basch, S. L. Brown, L. A. Kachnic, A. P. Dicker, C. N. Coleman, and P. Okunieff (2011)
Clin. Cancer Res.
17, 222-228
|Abstract »|Full Text »|PDF »
Sphingosine-1-Phosphate Activates the AKT Pathway to Protect Small Intestines from Radiation-Induced Endothelial Apoptosis.
S. Bonnaud, C. Niaudet, F. Legoux, I. Corre, G. Delpon, X. Saulquin, Z. Fuks, M.-H. Gaugler, R. Kolesnick, and F. Paris (2010)
Cancer Res.
70, 9905-9915
|Abstract »|Full Text »|PDF »